Floatz logo

Tisagenlecleucel

Burkitt Lymphoma

C. Babis AndreadisCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

46 Active assets in the Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
AIDS Malignancy Consortium
Phase 4BBB
METHOTREXATE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
Inno-206
AIDS Malignancy Consortium
Phase 4BBB
ETOPOSIDE
AIDS Malignancy Consortium
Phase 4BBB
Cytosin-Arabinosid
AIDS Malignancy Consortium
Phase 4BBB

View all 50 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →